PMC9520138_01
The histologic examination revealed a solid tumor mass with pleomorphic cells and a moderate desmoplastic stromal reaction (a: HE) and some cells with intracellular mucin deposits (b: PAS) (100 microm). Immunohistochemistry showed a focal reaction for cytokeratin 7 (c) and a strong proliferative activity for Ki67 (d) (100 microm). The staining for HER-2 was only weakly present in the tumor cells (e) and no staining could be seen for PD-L1 (f) (100 microm).. HE, hematoxylin and eosin; HER-2, human epidermal growth factor receptor 2; PAS, periodic acid Schiff; PD-L1, programmed death-ligand 1.
10.1177_17588359221125096-fig4.jpg
PMC9520138_01_10.1177_17588359221125096-fig4.jpg
fig4-17588359221125096
Table 1. The results of the histologic examination are shown in Figure 4.
MRI scan on the left side shows the diffuse lesion expansion after the fifth cycle of first-line chemotherapy. The scan on the right side shows the response after 3 months in which the patient is in complete remission.. MRI, magnetic resonance imaging.
10.1177_17588359221125096-fig5.jpg
PMC9520138_01_10.1177_17588359221125096-fig5.jpg
fig5-17588359221125096
A 74-year-old male was diagnosed with an advanced iCC of both liver lobes and pulmonary metastases (Figures 5 and 6). The treatment outcome was evaluated by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) before pemigatinib administration and after 3 months (Figures 5 and 6). In the pre- and post-MRI image data, an interactive tumor delineation method previously applied to liver CT data was used to determine the change in tumor size.   The images show a significant decrease in the tumor lesion volume from 453.9 to 133.7 ml after 3 months of treatment (Figure 5).
Display of complete metabolic remission 3 months after initiation of pemigatinib. Shown are MIPs (outer columns), transaxial slices of CT (inner upper column) as well as fused PET/CT (inner lower column). The patient initially presented with multiple pulmonary as well as hepatic metastases. The follow-up imaging revealed complete metabolic resolution of all lesions.. CT, computed tomography; MIPs, maximum intensity projections; PET, positron emission tomography.
10.1177_17588359221125096-fig6.jpg
PMC9520138_01_10.1177_17588359221125096-fig6.jpg
fig6-17588359221125096
A 74-year-old male was diagnosed with an advanced iCC of both liver lobes and pulmonary metastases (Figures 5 and 6). The treatment outcome was evaluated by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) before pemigatinib administration and after 3 months (Figures 5 and 6). The FDG-PET/CT revealed a complete functional remission of the iCC and lung metastases after 3 months of treatment (Figure 6).
Development of tumor markers during the clinical course and treatment. During therapy with pemigatinib, a significant decrease in the CA19-9 and CEA was observed resulting in a plateau representing complete remission.. CA, carbohydrate antigen; CEA, carcinoembryonic antigen.
10.1177_17588359221125096-fig7.jpg
PMC9520138_01_10.1177_17588359221125096-fig7.jpg
fig7-17588359221125096
Over the course of the treatment, tumor markers that were elevated at baseline measurement decreased to a plateau (Figure 7).